

Cite this: *Green Chem.*, 2019, **21**, 6731

# Muconic acid production from methane using rationally-engineered methanotrophic biocatalysts†

Calvin A. Henard, <sup>†,a</sup> Ilya R. Akberdin, <sup>§b,c</sup> Marina G. Kalyuzhnaya <sup>b</sup> and Michael T. Guarnieri <sup>\*a</sup>

Here, we demonstrate bioconversion of methane to muconic acid, a dicarboxylic acid that can be upgraded to an array of platform chemicals, by three gammaproteobacterial methanotrophs. All engineered methanotrophs expressing a heterologous dihydroxyshikimate dehydratase, protocatechuate decarboxylase, and catechol dioxygenase produced muconic acid from methane, with the highest titer (12.4 mg MA per L), yield (2.8 mg MA per g CH<sub>4</sub>), and specific productivity (1.2 mg MA per g dcw, 48 hr) synthesized by *Methylovimicrobium buryatense*, *Methylococcus capsulatus*, and *Methylovimicrobium alcaliphilum*, respectively. *Methylovimicrobium alcaliphilum* genome-scale model-guided strain engineering predicted that disruption of the pyruvate dehydrogenase or shikimate dehydrogenase would significantly enhance flux to the heterologous muconic acid pathway in this organism. However, knock-out of these targets caused a growth defect, and coupled with similar muconic acid titers (~1 mg L<sup>-1</sup>), resulted in minimal flux enhancement to muconic acid in these genetically-modified strains. The shikimate dehydrogenase mutant's ability to grow without aromatic amino acid supplementation revealed that *M. alcaliphilum* likely encodes an unidentified enzyme or pathway with shikimate biosynthetic capacity, which prevents maximal flux through the synthetic muconic acid pathway. This study expands the suite of products that can be generated from methane using methanotrophic biocatalysts, lays the foundation for green production of muconic acid-derived polymers from methane, and highlights the need for further analysis of methanotroph biosynthetic potential to guide refinement of metabolic models and strain engineering.

Received 29th October 2019,  
Accepted 8th November 2019

DOI: 10.1039/c9gc03722e

rsc.li/greenchem

## Introduction

Muconic acid (MA) is a dicarboxylic acid that can be upgraded to produce high-value commodity chemicals, including terephthalic acid, which in turn serves as a precursor for the production of polyester PET.<sup>1</sup> Additionally, MA is readily converted to adipic acid, a “top 50” bulk chemical, *via* hydrogenation, with high yield and specificity.<sup>2,3</sup> Adipic acid represents a multi-billion-dollar global market, with nylon-6,6 accounting for >85% of global adipic acid utilization.<sup>3</sup> The dicarboxylic functionality of adipic acid also affords a wide variety of

upgrading strategies including lactonization, diolization, and ketonization.<sup>1</sup> As such, adipic acid can be readily converted to other large-market, high-value molecules, such as plasticizers, lubricants, engineering resins, and polyurethanes. Conventional adipic acid production has been estimated to account for nearly 10% of global N<sub>2</sub>O emissions.<sup>4</sup> Though recent technologies have been deployed to help abate these emissions,<sup>5–8</sup> conventional routes to adipic acid production almost exclusively employ non-renewable, petroleum feedstocks, specifically ketone/alcohol (KA) oil generated *via* oxidation of cyclohexanone and cyclohexanol with nitric acid.<sup>4</sup> Thus, there is an increasing need to develop sustainable, green routes to produce MA and derivatives thereof.

Recently, a number of alternative bio-based MA production routes have been proposed, utilizing lignocellulosic aromatics and sugars as substrates for wild-type and genetically modified microbial biocatalysts.<sup>1–3,8</sup> MA biosynthesis naturally occurs during the catabolism of aromatic compounds in a subset of microorganisms, primarily saprophylic bacteria and fungi, which have ready access to plant-derived aromatics. Production of MA *via* heterologous pathway incorporation has

<sup>a</sup>National Bioenergy Center, National Renewable Energy Laboratory, Golden, CO, USA. E-mail: Michael.Guarnieri@nrel.gov, Calvin.Henard@unt.edu<sup>b</sup>Biology Department, San Diego State University, San Diego, CA, USA<sup>c</sup>Federal Research Center Institute of Cytology and Genetics SB RAS, Novosibirsk, Russia

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c9gc03722e

‡Current affiliation: Department of Biological Sciences and BioDiscovery Institute, University of North Texas, Denton, TX, USA.

§Current affiliation: BIOSOFT.RU, LLC, Novosibirsk, Russian Federation.



been demonstrated in heterotrophic bacteria and yeast by exploiting naturally occurring intermediary metabolic pathways involved in the detoxification or catabolism of aromatic compounds such as toluene and benzoate,<sup>1–3,9–11</sup> through catechol and protocatechuate intermediates. Alternatively, MA can be synthesized in a three-step process from the 3-dehydroshikimate (DHS) intermediate produced in the shikimate pathway,<sup>3</sup> which is essential for the synthesis of aromatic amino acids. Lastly, MA can also be generated by converting the anthranilate intermediate of tryptophan biosynthesis into catechol by the anthranilate 1,2-dioxygenase.<sup>12</sup> The above strategies have been successfully deployed in an array of model heterotrophic microbes, however, to date, there has been no demonstration of MA bioproduction from C1 carbon substrates.

Methanotrophic bacteria are promising hosts for carbon sequestration and conversion of C1 carbon streams to diverse target molecules, including fuel and chemical intermediates.<sup>13,14</sup> These bacteria are key global biochemical regulators capable of utilizing CH<sub>4</sub> as a carbon and energy source and possess core metabolic machinery enabling metabolic engineering strategies paralleling those found in conventional heterotrophic hosts.<sup>15,16</sup> These characteristics have led to intensified industrial interest for deployment of methanotrophs as production biocatalysts for bioconversion of gaseous waste streams, including anaerobic digestion-derived biogas,<sup>17,18</sup> which is primarily comprised of CH<sub>4</sub> and CO<sub>2</sub>. Indeed, recent efforts have demonstrated the potential utility of methanotrophic biocatalysts for production of platform chemicals from diverse waste streams.<sup>19–25</sup> Here, we present the first heterologous production of MA from CH<sub>4</sub> using methanotrophic bacteria as a production chassis. Further, we leveraged the *M. alcaliphilum* 20Z genome-scale model<sup>26</sup> to guide rational metabolic engineering to increase carbon flux to the MA pathway, which revealed a yet unidentified shikimate biosynthetic enzyme or pathway in this organism. These results underscore that further elucidation of methanotroph central metabolism is required to accurately model and predict methanotrophic biosynthetic capacity.

## Results and discussion


Methanotrophs are not known to naturally produce MA. However, these bacteria encode genes requisite for *de novo* aromatic amino acid biosynthesis and can be cultivated on minimal media lacking amino acid supplementation, indicating that the upstream metabolic machinery for shikimate pathway-derived MA production is present. Leveraging this metabolic machinery, we incorporated a MA biosynthetic pathway encoding the *Bacillus thuringiensis* AsbF dihydroxyshikimate acid dehydratase, *Enterobacter cloacae* AroY protocatechuate decarboxylase, and an *Acinetobacter* sp. CatAP76A catechol dioxygenase variant<sup>27</sup> in order to shunt the aromatic amino acid precursor dihydroxyshikimate acid to MA in methanotrophic bacteria (Fig. 1A). The resultant vector, pMUC, was introduced into *Methylotuvimicrobium alcaliphilum* 20Z<sup>R</sup>,

*Methylotuvimicrobium buryatense* 5G, and *Methylococcus capsulatus* Bath, industrially-promising gammaproteobacterial methanotrophs with established metabolic engineering tools, including genome-scale metabolic models.<sup>26,28–30</sup> Quantitative reverse-transcription PCR (qRT-PCR) analysis of the engineered strains harboring the biosynthetic pathway under the control of the inducible tetracycline promoter/operator<sup>22</sup> indicated that this promoter is functional in all three methanotrophic strains, with significant expression of AsbF, AroY, and CatA-encoding genes detected after induction (Fig. 1B).


We evaluated growth and MA production by the pMUC strains in 0.5 L continuous-stirred tank reactors (CSTRs) with constant gas supply (20% CH<sub>4</sub> v/v in air, 1 vvm; 2% CO<sub>2</sub> was also supplied to *M. capsulatus* Bath). All strains excreted MA during active growth, coincident with carbon flux through the shikimate pathway to provide proteinogenic aromatic amino acids (Fig. 2). We did not detect the MA precursors protocatechuic acid and catechol in the culture medium, contrary to prior studies using yeast or bacterial biocatalysts expressing a similar heterologous MA biosynthetic pathway.<sup>2,3,31</sup> *M. alcaliphilum* and *M. capsulatus* reached cell densities of OD<sub>600</sub> = 6–8 after 48 h, excreting MA at titers of 0.75 mg L<sup>–1</sup> and 0.97 mg L<sup>–1</sup> MA, respectively (Fig. 2A and B, Table 1). We previously increased the growth potential of *M. buryatense* in CSTR cultivation *via* media optimization, achieving maximum OD<sub>600</sub> ~ 50 culture densities.<sup>21,22</sup> Under these optimized cultivation conditions, *M. buryatense* excreted 12.4 mg L<sup>–1</sup> MA into the culture medium following 48 h of cultivation (Fig. 2C and Table 1), which is comparable with other proof-of-concept product titers (10–100 mg L<sup>–1</sup>) produced by engineered methanotrophs.<sup>19,22–24,32</sup> Although we were able to increase the MA titer by high-density cell cultivation, yields (0.65–2.7 mg MA per g CH<sub>4</sub>) and specific productivities (0.68–1.2 mg MA per g DCW) were comparable between the engineered methanotrophs, with *M. capsulatus* exhibiting the highest yield. *M. alcaliphilum* exhibited the highest specific productivity (Table 1), which served as the basis for down-selection and further evaluation.

We leveraged our previously developed *M. alcaliphilum* genome-scale model (GSM)<sup>26</sup> to identify genetic targets for increased carbon flux to the MA pathway. Based on the GSM, the maximum theoretical specific productivity of MA production is 0.2 g MA per g DCW. Disruption of the shikimate dehydrogenase (encoded by MALCv4\_3465) and the pyruvate dehydrogenase (encoded by MALCv4\_1357-9) were predicted by the model to significantly increase flux through the heterologous MA pathway (Table 2). This agrees with other studies where disruption of the shikimate dehydrogenase is required in heterotrophic hosts to achieve heterologous MA biosynthesis from aromatic amino acid precursors by inhibiting flux through the shikimate pathway and increasing DHS substrate availability,<sup>1,3,31</sup> while disruption of pyruvate dehydrogenase would be predicted to increase availability of phosphoenolpyruvate and erythrose-4-phosphate shikimate pathway precursors. We introduced the heterologous MA biosynthetic pathway into our previously generated *M. alcaliphilum* pyruvate





**Fig. 1** Metabolic engineering of methanotrophic bacteria for biogas conversion to muonic acid. (A) Schematic of the three-enzyme heterologous biochemical pathway used to convert the dihydroxyshikimate (DHS) shikimate pathway precursor to muonic acid in methanotrophs. (B) qRT-PCR analysis of muonic acid biosynthetic pathway genes in *M. alcaliphilum* 20Z<sup>R</sup>, *M. capsulatus* Bath, and *M. buryatense* 5G engineered strains.



**Fig. 2** Muonic acid production by methanotrophic bacteria in bioreactors with continuous biogas supply. (A) *Methylothermobacterium alcaliphilum*, (B) *Methylococcus capsulatus*, and (C) *Methylothermobacterium buryatense* growth (black circles) and muonic acid titer (MA, red circles) were measured in continuously stirred tank bioreactors supplied with 20% CH<sub>4</sub> in air at 1 volume of gas/volume of medium/minute. *M. capsulatus* reactors were also supplemented with 2% CO<sub>2</sub>.

dehydrogenase knock-out strain<sup>20</sup> and evaluated MA production in CSTRs (Table 2). The pMUC  $\Delta pdh$  strain produced similar MA titers but displayed a growth defect compared to

the pMUC strain; thus a 1.5-fold increase in specific productivity was observed, albeit much lower than the 23.2-fold flux increase predicted by the GSM (Table 2). The discrepancy



**Table 1** Muconate titer, yield, and specific productivity in stirred bioreactors

Strain	Titer (mg MA per L/48 h)	CH <sub>4</sub> consumed (g L <sup>-1</sup> /48 h)	Maximum yield (mg MA per g CH <sub>4</sub> , 24–48 h)	Specific productivity (mg MA per g DCW, 48 h)
<i>M. alcaliphilum</i> pMUC	0.75 ± 0.08	1.35 ± 0.33	0.65 ± 0.12	1.2 ± 0.01
<i>M. capsulatus</i> pMUC	0.97 ± 0.21	0.74 ± 0.07	2.8 ± 0.04	0.68 ± 0.16
<i>M. buryatense</i> pMUC	12.4 ± 2.26	12.5 ± 0.14	1.2 ± 0.22	1.1 ± 0.20

The data represent the mean ± standard deviation of two biological replicate bioreactors.

**Table 2** *M. alcaliphilum* 20Z<sup>R</sup> genome-scale model genetic alteration flux predictions and engineered strain bioreactor relative productivity metrics for muconic acid (MA), lactic acid (LA), and biomass


Strain	Predicted MA flux ratio	Observed max MA flux ratio	Observed max LA flux ratio	Biomass (g DCW, 96 h)
20Z <sup>R</sup> pMUC	1	0.91 ± 0.13	0.84 ± 0.22	0.69 ± 0.008
20Z <sup>R</sup> pMUC $\Delta$ <i>pdh</i>	23.2	1.5 ± 0.07	4.0 ± 0.06	0.35 ± 0.02
20Z <sup>R</sup> pMUC $\Delta$ <i>aroE</i>	29.4	1.0 ± 0.11	1.4 ± 0.53	0.31 ± 0.04

The data represent the mean ± standard deviation of two biological replicate bioreactors.

between predicted and actual flux values could be in part due to the high lactic acid flux observed in this strain (Table 2), presumably because of increased pyruvate availability and conversion by the native lactate dehydrogenase.

We hypothesized that knock-out of MALCv4\_3465 would result in an aromatic amino acid auxotrophic strain similar to that observed in *Escherichia coli*. We successfully removed the locus *via* marker exchange mutagenesis (Fig. 3A). However, a MALCv4\_3465 mutant ( $\Delta$ *aroE*) was successfully isolated in the absence of shikimate or aromatic amino acid supplementation, suggesting an alternate shikimate biosynthetic pathway is present in *M. alcaliphilum*. To assess the potential for increased DHS substrate availability in the *M. alcaliphilum*  $\Delta$ *aroE* strain, we introduced pMUC and analyzed MA production in CSTRs. Similar to the pMUC  $\Delta$ *pdh* strain, the pMUC  $\Delta$ *aroE* strain displayed a slight growth defect but a similar MA specific productivity relative to the isogenic pMUC strain

(Table 2). The GSM predicted that removal of the shikimate dehydrogenase would increase flux through the MA pathway by 29.4-fold and result in aromatic amino acid auxotrophy with no carbon flux to biomass. Although deletion of MALCv4\_3465 decreased *M. alcaliphilum* growth, the  $\Delta$ *aroE* strain's ability to grow in the absence of shikimate or aromatic amino acid supplementation provides additional support for the presence of an alternative shikimate biosynthetic enzyme encoded by *M. alcaliphilum*. To confirm accurate gene annotation of MALCv4\_3465 as a shikimate dehydrogenase, we tested the ability of MALCv4\_3465 to complement an *E. coli* shikimate dehydrogenase KO strain that does not grow on M9 minimal medium without aromatic amino acid supplementation.<sup>33</sup> Successful complementation of the *E. coli*  $\Delta$ *aroE* non growth phenotype in M9 medium was achieved *via* plasmid-based expression of the *E. coli* *aroE* gene or MALCv4\_3465, supporting that MALCv4\_3465 encodes a functional shikimate dehydrogenase (Fig. 3B), and provides an additional line of evidence that *M. alcaliphilum* encodes an alternative shikimate biosynthetic enzyme. However, alternative AroE or YdiB homologs<sup>34</sup> were not identified in the *M. alcaliphilum* 20Z<sup>R</sup> genome *via* homology query. Based on previous metabolic engineering efforts to produce MA from non-aromatic substrates in heterotrophic hosts, increasing flux to the DHS substrate *via* gene disruption, pathway over-expression, and/or generation of feedback-insensitive shikimate pathway enzymes are requisite for efficient MA production from non-aromatic precursors.<sup>35</sup> Thus, a complete understanding of shikimate biosynthetic pathways is needed to more accurately predict competing metabolic pathways and



**Fig. 3** *M. alcaliphilum* 20Z<sup>R</sup> MALCv4\_3465 rescues the auxotrophic phenotype of an *E. coli* shikimate dehydrogenase knockout. (A) Confirmation of the *M. alcaliphilum* MALCv4\_3465 knockout strain *via* PCR analysis (B) Auxotrophic complementation of an *E. coli* shikimate dehydrogenase (*aroE*) knockout strain in M9 minimal medium *via* plasmid-based expression of *E. coli* AroE (p*EcaroE*) or *M. alcaliphilum* AroE (MALCv4\_3465, p20*ZaroE*).





guide future rational metabolic engineering pursuits to increase MA production metrics in *M. alcaliphilum*.

Notably, the highest yield observed in this study (2.7 mg MA per g CH<sub>4</sub>) is comparable to initial MA yields produced by heterotrophic biocatalysts expressing a similar heterologous MA biosynthetic pathway.<sup>3,31</sup> MA yields from glucose in these heterotrophic hosts have been significantly improved (12.9 mg MA per g glucose) *via* additional genetic modifications for increased flux to the MA pathway, including removal of aromatic amino acid negative feedback regulation and disruption/modification of the shikimate dehydrogenase that was attempted in *M. alcaliphilum* here.<sup>3,35–38</sup> These results indicate a substantial yield enhancement can be achieved if an alternative shikimate biosynthetic route can be identified and disrupted. Future strain engineering efforts for efficient MA production from CH<sub>4</sub> will thus entail identification and disruption of the unidentified shikimate biosynthetic enzyme, as well as homologous overexpression of transketolase and/or phosphoketolase for increased erythrose-4-phosphate substrate availability, and expression of either a native or heterologous feedback insensitive 2-dehydro-3-deoxyphosphoheptone (DAHP) aldolase variant to increase flux through the shikimate pathway.

## Conclusions

CH<sub>4</sub> is the second most abundant greenhouse gas (GHG), with increased warming potential relative to CO<sub>2</sub>. Nearly 60% of CH<sub>4</sub> emissions are derived from anthropogenic sources, including shale gas fracking, landfill gases, and industrial agriculture operations. Further, CH<sub>4</sub> is the primary component of natural gas and anaerobic digestion-derived biogas, and recent reports have indicated CH<sub>4</sub> represents a high-volume, low-cost substrate that is well-suited for biomanufacturing.<sup>13,39</sup> Importantly, the conversion of natural gas and biogas can simultaneously offset petroleum usage while mitigated GHGs with massive economic and environmental impacts.<sup>40</sup> In contrast to heterotrophic microbial conversion strategies employing biomass-derived substrates, the utilization of CH<sub>4</sub> as a bioconversion substrate does not compete with food production. Thus, strategies that convert CH<sub>4</sub> to high-value intermediates present an opportunity to mitigate and sequester GHG emissions, while concurrently valorizing CH<sub>4</sub>. Additionally, CH<sub>4</sub> biocatalysis offers a means to concurrently liquefy and upgrade CH<sub>4</sub>, enabling its utilization in conventional transportation and industrial manufacturing infrastructure. To this end, recent efforts have successfully generated methanotrophic biocatalysts with diverse production capacity for fuel and chemical intermediates.<sup>17,19–25</sup>

The work presented here provides proof-of-concept for production of MA from CH<sub>4</sub>. Methanotrophic production of MA from CH<sub>4</sub> presents a novel, green pathway to biosynthesize a key platform intermediate capable of displacing petroleum in the production of high-volume commodity chemicals and biopolymers. However, a series of biological and process limit-

ations will need to be addressed to achieve economically-viable production. A primary biological driver is the identification and disruption of alternative shikimate biosynthetic genes, which will enable increased flux to MA precursors. Genome-wide mutagenic approaches offer a promising route to identify auxotrophic phenotypes, implicating genes with redundant functionality. Lastly, conventional gas fermentation challenges remain a hurdle; gas mass transfer limitations, in particular, will need to be addressed in order to achieve economically-viable production rates.

## Materials and methods

### Bacterial strains

*Methylotuvimicrobium* (previously *Methylomicrobium*) *alcaliphilum* 20Z<sup>R</sup>,<sup>26</sup> *Methylotuvimicrobium buryatense* 5GB1,<sup>28</sup> and *Methylococcus capsulatus* Bath (Table S1†) were cultivated in either nitrate mineral salts (NMS) medium (Bath) or NMS medium supplemented with 1.5% NaCl and carbonate buffer as previously described.<sup>41–43</sup> Strains were routinely maintained on solid medium in stainless-steel gas chambers (Schuett-biotec GmbH) containing 20% (v/v) methane in air.

### Muconic acid biosynthetic pathway construction

Plasmids and primers used in this study are presented in Table S2.† The muconic acid biosynthetic pathway was constructed by ligating codon-optimized *asbF*-encoding dehydroshikimate dehydratase from *Bacillus thuringiensis*, *aroY*-encoding protocatechuate decarboxylase from *Enterobacter cloacae*, and the *catA*-encoding catechol dioxygenase P76A variant from *Acinetobacter baylyi* (codon-optimized gene sequences are in Table S3†) into the pCAH01 inducible expression vector<sup>22</sup> to generate pMUC using 2× Gibson Assembly Mix from New England Biolabs (Ipswich, MA), following the manufacturers protocol. The pMUC vector sequence was confirmed by sequence analysis (Genewiz, South Plainfield, NJ). This vector was transformed into the methanotrophic strains *via* biparental mating using *E. coli* S17 as previously described.<sup>28,42</sup> Positive transformants selected on solid medium containing 100 µg mL<sup>-1</sup> of kanamycin were confirmed by PCR and sequence analysis.

### Quantitative reverse transcription PCR

Total RNA was isolated from cultures grown for 48 h on solid medium with and without pMUC induction with 0.5 µg mL<sup>-1</sup> anhydrotetracycline inducer using the Monarch Total RNA miniprep kit (New England Biolabs) followed by removal of contaminating DNA by treatment with Turbo DNase (Life Technologies, Carlsbad, CA). cDNA was synthesized from 1 µg total RNA using the SuperScript VILO cDNA synthesis kit (ThermoFisher) following the manufacturer's protocol. Real-time PCR was performed by using SYBR IQ master mix and a QuantStudio Real-Time PCR System (ThermoFisher). The primers used for the qRT-PCR are listed in Table S2.† The cycle threshold (Ct) value for each gene was determined and



normalized to the *rpoD* gene encoding the RNA polymerase housekeeping sigma factor. Relative expression between induced and uninduced control samples was calculated by using the  $\Delta\Delta C_t$  method.

### Methane fermentations

100 mL seed cultures were inoculated from plate biomass and grown in 150 mL bubble columns with a continuous gas flow (20% CH<sub>4</sub>, in air, 1 volume of gas per volume of liquid per minute (vvm)). *M. capsulatus* Bath cultures were also supplied with 2% CO<sub>2</sub> in the gas mixture. Gas fermentations were performed in a 0.5 L Biostat-Q plus bioreactor (Sartorius, Gottingen, Germany) with a culture volume of 300 mL. The *M. buryatense* bioreactor medium was supplemented with 8× KNO<sub>3</sub> (80 mM), 2× phosphate buffer (4.6 mM), and 4× trace element solution to support high cell growth, as previously described.<sup>22,44</sup> Seed cultures were diluted to a final OD<sub>600</sub> = 0.1–0.5. Mixing was achieved by using a bottom marine impeller at 500 rpm. A continuous flow rate of 1 vvm 20% CH<sub>4</sub> in air (plus 2% CO<sub>2</sub> for *M. capsulatus* Bath) was maintained for the duration of cultivation. At indicated intervals, growth was measured spectrophotometrically at 600 nm and a 1 mL sample was taken for HPLC analysis. The culture supernatant was filtered using a 0.2 µm syringe filter and then a 0.1 mL injection was separated using a model 1260 HPLC (Agilent, Santa Clara, CA) and a cation H HPX-87H column (Bio-Rad). A 0.6 mL min<sup>−1</sup> flow rate at 55 °C with 0.01 N sulfuric acid as the mobile phase was used. Refractive index and diode array detectors were used for compound detection. Muconic acid concentrations were calculated by regression analysis compared to known standards with the minimum detection limit of 0.2 mg L<sup>−1</sup> muconic acid. The percent CH<sub>4</sub> in the off-gas was measured every 10 min for the duration of bioreactor fermentations *via* mass spectrometry. Percent CH<sub>4</sub> consumption was converted to weight based on CH<sub>4</sub> density (0.000656 g mL<sup>−1</sup>) and the flow rate (60 mL CH<sub>4</sub> per min). Dry Cell Weight (DCW) was either measured directly after freeze-drying or estimated from the final OD of the cell culture using the following equation: DCW = OD × (0.35 ± 0.04) g L<sup>−1</sup>.<sup>26</sup> Muconic acid yields were calculated using consumed substrate data and represented as mg muconic acid produced per g CH<sub>4</sub> consumed.

### *M. alcaliphilum* shikimate dehydrogenase mutant construction

Plasmids and primers used for amplification of the shikimate dehydrogenase flanking regions and the pK18mobsacB vector for construction of the shikimate dehydrogenase (*aroE*) knock-out are shown in Tables S1 and S2.† 1000 bp genomic fragments flanking the shikimate dehydrogenase (MALCv4\_3465) gene were amplified by PCR and cloned into the pK18mobsacB plasmid *via* Gibson assembly. The resulting plasmid was introduced to the 20Z<sup>R</sup> strain by biparental conjugation as described previously.<sup>28</sup> Positive transformants selected on medium supplemented with kanamycin (100 µg mL<sup>−1</sup>) were subsequently plated on medium containing 2.5% sucrose for counterselection to remove the kanamycin resis-

tance marker. Sucrose-resistant, kanamycin-sensitive colonies were PCR-genotyped for removal of the MALCv4\_3465 locus.

### *E. coli* shikimate dehydrogenase mutant complementation

The *E. coli* shikimate dehydrogenase *aroE* and *M. alcaliphilum* 20Z<sup>R</sup> MALCv4\_3465 genes with native ribosomal binding sites were amplified from the corresponding genomic DNA using primers appending XbaI and HindIII restriction sites to the 5' and 3' ends (Table S2†), respectively. Genes were directionally cloned into the pBluescript II KS+ vector. Expression constructs were sequence verified and transformed into the JW3242  $\Delta$ *aroE721::kan* parent strain *via* electroporation. Positive transformants selected on LB medium containing kanamycin and ampicillin were grown in M9 minimal medium supplemented with 0.5 mM IPTG for shikimate dehydrogenase induction. Bacterial growth of the complementing strains in M9 medium was compared to wild-type *E. coli* BW25113 and JW3242  $\Delta$ *aroE721::kan* parent strains, the latter of which does not grow on M9 medium.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We would like to thank Holly Rohrer of the National Renewable Energy Laboratory for technical assistance. Funding provided by the U.S. Department of Energy Office of Energy Efficiency and Renewable Energy Bioenergy Technologies Office DE-FOA-0001085. This work was authored in part by Alliance for Sustainable Energy, LLC, the manager and operator of the National Renewable Energy Laboratory for the U.S. Department of Energy under Contract No. DE-AC36-08GO28308. The views expressed in the article do not necessarily represent the views of the DOE or the U.S. Government. The U.S. Government retains and the publisher, by accepting the article for publication, acknowledges that the U.S. Government retains a non-exclusive, paid-up, irrevocable, worldwide license to publish or reproduce the published form of this work, or allow others to do so, for U.S. Government purposes.

## References

- 1 N.-Z. Xie, H. Liang, R.-B. Huang and P. Xu, *Biotechnol. Adv.*, 2014, **32**, 615–622.
- 2 C. Weber, C. Brückner, S. Weinreb, C. Lehr, C. Essl and E. Boles, *Appl. Environ. Microbiol.*, 2012, **78**, 8421–8430.
- 3 K. A. Curran, J. M. Leavitt, A. S. Karim and H. S. Alper, *Metab. Eng.*, 2013, **15**, 55–66.
- 4 K. Sato, M. Aoki and R. Noyori, *Science*, 1998, **281**, 1646–1647.
- 5 M. Zhao, D. Huang, X. Zhang, M. A. G. Koffas, J. Zhou and Y. Deng, *Metab. Eng.*, 2018, **47**, 254–262.



- 6 K. Raj, S. Partow, K. Correia, A. N. Khusnutdinova, A. F. Yakunin and R. Mahadevan, *Metab. Eng. Commun.*, 2018, **6**, 28–32.
- 7 T. Babu, E. J. Yun, S. Kim, D. H. Kim, K. H. Liu, S. R. Kim and K. H. Kim, *Process Biochem.*, 2015, **50**, 2066–2071.
- 8 D. R. Vardon, M. A. Franden, C. W. Johnson, E. M. Karp, M. T. Guarnieri, J. G. Linger, M. J. Salm, T. J. Strathmann and G. T. Beckham, *Energy Environ. Sci.*, 2015, **8**, 617–628.
- 9 J. Becker, M. Kuhl, M. Kohlstedt, S. Starck and C. Wittmann, *Microb. Cell Fact.*, 2018, **17**, 115.
- 10 T. Sonoki, K. Takahashi, H. Sugita, M. Hatamura, Y. Azuma, T. Sato, S. Suzuki, N. Kamimura and E. Masai, *ACS Sustainable Chem. Eng.*, 2018, **6**, 1256–1264.
- 11 D. Salvachua, C. W. Johnson, C. A. Singer, H. Rohrer, D. J. Peterson, B. A. Black, A. Knapp and G. T. Beckham, *Green Chem.*, 2018, **20**, 5007–5019.
- 12 X. Sun, Y. Lin, Q. Huang, Q. Yuan and Y. Yan, *Appl. Environ. Microbiol.*, 2013, **79**, 4024–4030.
- 13 J. M. Clomburg, A. M. Crumbley and R. Gonzalez, *Science*, 2017, 355.
- 14 R. J. Conrado and R. Gonzalez, *Science*, 2014, **343**, 621–623.
- 15 L. Chistoserdova, M. G. Kalyuzhnaya and M. E. Lidstrom, *Annu. Rev. Microbiol.*, 2009, **63**, 477–499.
- 16 M. G. Kalyuzhnaya, S. Yang, O. N. Rozova, N. E. Smalley, J. Clubb, A. Lamb, G. A. N. Gowda, D. Raftery, Y. Fu, F. Bringel, S. Vuilleumier, D. A. C. Beck, Y. A. Trotsenko, V. N. Khmelenina and M. E. Lidstrom, *Nat. Commun.*, 2013, **4**, 2785.
- 17 C. A. Henard and M. T. Guarnieri, in *Methane biocatalysis: paving the way to sustainability*, ed. M. G. Kalyuzhnaya and X.-H. Xing, Springer International Publishing, Cham, 2018, pp. 117–132.
- 18 M. G. Kalyuzhnaya, A. W. Puri and M. E. Lidstrom, *Metab. Eng.*, 2015, **29**, 142–152.
- 19 D. T. N. Nguyen, O. K. Lee, S. Hadiyati, A. N. Affifah, M. S. Kim and E. Y. Lee, *Metab. Eng.*, 2019, **54**, 170–179.
- 20 C. A. Henard, T. G. Franklin, B. Youhenna, S. But, D. Alexander, M. G. Kalyuzhnaya and M. T. Guarnieri, *Front. Microbiol.*, 2018, **9**, 2610.
- 21 C. A. Henard, H. K. Smith and M. T. Guarnieri, *Metab. Eng.*, 2017, **41**, 152–158.
- 22 C. A. Henard, H. Smith, N. Dowe, M. G. Kalyuzhnaya, P. T. Pienkos and M. T. Guarnieri, *Sci. Rep.*, 2016, **6**, 21585.
- 23 S. Garg, H. Wu, J. M. Clomburg and G. N. Bennett, *Metab. Eng.*, 2018, **48**, 175–183.
- 24 A. D. Nguyen, I. Y. Hwang, O. K. Lee, D. Kim, M. G. Kalyuzhnaya, R. Mariyana, S. Hadiyati, M. S. Kim and E. Y. Lee, *Metab. Eng.*, 2018, **47**, 323–333.
- 25 S. Garg, J. M. Clomburg and R. Gonzalez, *J. Ind. Microbiol. Biotechnol.*, 2018, **45**, 379–391.
- 26 I. R. Akberdin, M. Thompson, R. Hamilton, N. Desai, D. Alexander, C. A. Henard, M. T. Guarnieri and M. G. Kalyuzhnaya, *Sci. Rep.*, 2018, **8**, 2512.
- 27 L. Han, P. Liu, J. Sun, Y. Wu, Y. Zhang, W. Chen, J. Lin, Q. Wang and Y. Ma, *Sci. Rep.*, 2015, **5**, 13435.
- 28 A. W. Puri, S. Owen, F. Chu, T. Chavkin, D. A. C. Beck, M. G. Kalyuzhnaya and M. E. Lidstrom, *Appl. Environ. Microbiol.*, 2015, **81**, 1775–1781.
- 29 A. de la Torre, A. Metivier, F. Chu, L. M. L. Laurens, D. A. C. Beck, P. T. Pienkos, M. E. Lidstrom and M. G. Kalyuzhnaya, *Microb. Cell Fact.*, 2015, **14**, 188.
- 30 C. Lieven, L. A. H. Petersen, S. B. Jørgensen, K. V. Gernaey, M. J. Herrgard and N. Sonnenschein, *Front. Microbiol.*, 2018, **9**, 2947.
- 31 C. W. Johnson, D. Salvachua, P. Khanna, H. Smith, D. J. Peterson and G. T. Beckham, *Metab. Eng. Commun.*, 2016, **3**, 111–119.
- 32 L. T. Nguyen and E. Y. Lee, *Biotechnol. Biofuels*, 2019, **12**, 147.
- 33 T. Baba, T. Ara, M. Hasegawa, Y. Takai, Y. Okumura, M. Baba, K. A. Datsenko, M. Tomita, B. L. Wanner and H. Mori, *Mol. Syst. Biol.*, 2006, **2**, 2006.0008.
- 34 G. Michel, A. W. Roszak, V. Sauvé, J. Maclean, A. Matte, J. R. Coggins, M. Cygler and A. J. Lapthorn, *J. Biol. Chem.*, 2003, **278**, 19463–19472.
- 35 N. J. H. Aversch and J. O. Krömer, *Front. Bioeng. Biotechnol.*, 2018, **6**, 32.
- 36 J. M. Leavitt, J. M. Wagner, C. C. Tu, A. Tong, Y. Liu and H. S. Alper, *Biotechnol. J.*, 2017, **12**(10), DOI: 10.1002/biot.201600687.
- 37 M. Suastegui, J. E. Matthiesen, J. M. Carraher, N. Hernandez, N. Rodriguez Quiroz, A. Okerlund, E. W. Cochran, Z. Shao and J.-P. Tessonier, *Angew. Chem., Int. Ed.*, 2016, **55**, 2368–2373.
- 38 W. Niu, K. M. Draths and J. W. Frost, *Biotechnol. Prog.*, 2002, **18**, 201–211.
- 39 A. D. Comer, M. R. Long, J. L. Reed and B. F. Pfleger, *Metab. Eng. Commun.*, 2017, **5**, 26–33.
- 40 Biogas Opportunities Roadmap, Department of Energy, <https://www.energy.gov/downloads/biogas-opportunities-roadmap>.
- 41 R. Whittenbury, K. C. Phillips and J. F. Wilkinson, *J. Gen. Microbiol.*, 1970, **61**, 205–218.
- 42 D. S. Ojala, D. A. C. Beck and M. G. Kalyuzhnaya, *Methods Enzymol.*, 2011, **495**, 99–118.
- 43 T. Tapscott, M. T. Guarnieri and C. A. Henard, *Appl. Environ. Microbiol.*, 2019, **85**(11), DOI: 10.1128/AEM.00340-19.
- 44 Q. Fei, A. W. Puri, H. Smith, N. Dowe and P. T. Pienkos, *Biotechnol. Biofuels*, 2018, **11**, 129.

